BioSyngen
PrivateLast Round
Early Funding
Oct 20, 2021
Total Funding Raised
$43.5M
Company Overview
BioSyngen operates in Healthcare & Life Sciences and is based in Singapore. Its latest recorded funding round was an Early Funding round in October 2021.
BioSyngen is a biotechnology company that develops first-in-class cell therapies, including CAR-T, TCR-T, and TILs, to treat solid tumors and other cancers.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
BioSyngen Comparables
Compare BioSyngen with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| TCRCure Biopharma | 87% | |
| Lion TCR | 84% | |
| SCG Cell Therapy | 84% |
For institutional investors. Book with your work email.
BioSyngen Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
BioSyngen Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Science City (Guangzhou) Investment Group Co., Ltd. | Early Funding |
Recent news
Latest coverage and updates
- is_developingAug 27, 2026
Biosyngen Pte. Ltd. is partnering with Zhujiang Hospital of Southern Medical University to establish an international medical platform for immune cell therapy for solid tumours, including joint clinical research, a shared research and development and translation platform, and talent development in the Greater Bay Area.
For institutional investors. Book with your work email.
BioSyngen Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about BioSyngen's valuation, stock price, and market status.
Is BioSyngen a public or private company?
BioSyngen is a private company.
What is the current stock price of BioSyngen?
BioSyngen is a private company, so its shares have no public market price. Caplight tracks BioSyngen's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is BioSyngen worth (valuation)?
Valuation information for BioSyngen is not publicly available.
Can I buy BioSyngen stock?
BioSyngen shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was BioSyngen's last funding round?
BioSyngen's most recent funding round was Early Funding on October 20, 2021.
Who are the main investors in BioSyngen?
Key investors in BioSyngen include Science City (Guangzhou) Investment Group Co., Ltd..
Will BioSyngen IPO soon?
No public IPO plans have been announced for BioSyngen.
How can I track BioSyngen secondary market activity?
Caplight tracks bids, offers, and trades in BioSyngen's shares on secondary markets.